Stage
No active trials
Next date
None yet
Trials
0 active
2 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “* Pharmaceutical form: oral capsules * Concentration: 10 and 50 mg * Route of administration: oral administration”In the company’s words, NCT00152451 on ClinicalTrials.gov
- Tested for
- Epilepsy, Partial (2 trials)
- Main trialPhase 2
- “This trial will evaluate the efficacy and safety of ucb 44212 as add on therapy in subjects with focal epilepsy.”In the company’s words, NCT00152451 on ClinicalTrials.gov
Other drugs for Epilepsy, Partial
- BHV-7000Biohaven · Phase 2/3
- CenobamateSK Life Science, Inc. · Phase 3
- VormatroginePraxis Precision Medicines · Phase 3
- RAP-219Rapport Therapeutics Inc. · Phase 3
- AzetukalnerXenon Pharmaceuticals Inc. · Phase 3
- NRTX-1001Neurona Therapeutics · Phase 1/2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Completed | 3 May 2006 | Study With Seletracetam (Ucb 44212) in Adult Subjects (18 to 65 Years) With Partial Onset Seizures | |
| Phase 2Completed | 12 May 2006 | Study With Subjects 18-65 Years Old With Partial Onset Seizures Who Are Currently Taking Levetiracetam |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026